This is a case-based activity that includes discussion of A 53 year old male with a history of GERD now with three months of worsening dysphagia + odynophagia, and a 15 pound weight loss. His esophagogastroduodenoscopy (EGD) showed a mass - 36-40 cm (Distal esophagus to gastroesophageal junction [GEJ]). Along with the patient case, there is a discussion board on ASCO Connection, where users can post comments/questions to each other and to the faculty. At the end of this course you should be able to:
1. Understand the potential roles of neoadjuvant chemotherapy, peri-operative chemotherapy and combined modality therapy with surgery in the treatment of patients with esophageal and GEJ cancers.
2. Review the Level 1 evidence in the treatment of patients with localized esophageal and GEJ cancers and its clinical implications.
3. Describe level one evidence for first and second line chemotherapy in metastatic esophageal and GE junction cancer.
4. Review the current status of targeted agents in esophageal and GE junction cancer including Her2, EGFr, and VEGFr targeted therapy
This activity was made available on 2/18/2015 and will be reviewed on an annual basis to determine continued availability. A maximum of 1 AMA PRA Category 1 Credit(s) ™ credit is available.
Medical Knowledge (ACGME, AAPA)
Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)
Note: This course is now accessible through mobile devices as well as personal computers